Lyell Immunopharma (NASDAQ:LYEL) & Century Therapeutics (NASDAQ:IPSC) Critical Analysis

Century Therapeutics (NASDAQ:IPSC) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Profitability

This table compares Century Therapeutics and Lyell Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Analyst Ratings

This is a breakdown of current ratings and target prices for Century Therapeutics and Lyell Immunopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1	2	4	0	2.43
Lyell Immunopharma	1	1	6	1	2.78

Century Therapeutics currently has a consensus price target of $4.75, suggesting a potential upside of 219.01%. Lyell Immunopharma has a consensus price target of $40.86, suggesting a potential upside of 270.08%. Given Lyell Immunopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Century Therapeutics.

Volatility and Risk

Century Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Insider and Institutional Ownership

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 66.0% of Lyell Immunopharma shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Century Therapeutics and Lyell Immunopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16 million	2.47	-$9.58 million	($0.93)	-1.60
Lyell Immunopharma	$40,000.00	6,762.00	-$274.45 million	($12.83)	-0.86

Century Therapeutics has higher revenue and earnings than Lyell Immunopharma. Century Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Lyell Immunopharma beats Century Therapeutics on 8 of the 15 factors compared between the two stocks.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.